Siobhán Kelleher, PhD
Competition Sponsor: EIT Health of the European Union
At Sision Medical, we make invisible chronic endocrine conditions, such as endometriosis, which impact the most productive years of patient’s lives, visible. We apply digital biomarker insights to deliver optimal bioelectronic treatment at the best time to each patient, thereby better identifying and managing high-risk and high-cost patients.
Endometriosis affects one in ten women of reproductive age, that’s 176 million women worldwide, and is characterised by debilitating chronic pelvic pain and infertility. The annual societal burden in the USA is estimated to be $69 billion. She Sync is a wearable, smartphone-controlled bio-electronic device which has the potential to reduce endometriosis-associated pain without the hormonal side-effects associated with current medications and the risks associated with surgery, which is currently how endometriosis is treated. We are reforming the entire care pathway, from diagnosis to treatment and subsequent monitoring of disease progression. Our unique digital biomarker offers many benefits; (i) earlier diagnosis of women with endometriosis (ii) selection of women for whom She Sync will provide best treatment outcomes, (iii) monitoring of progression or recurrence of the disease without the requirement for surgery and (iv) value to over-stretched healthcare budgets. With growing awareness of endometriosis and pressure on healthcare budgets for treatment of chronic disease, this approach brings value not only to patients and their physicians but to healthcare systems and society at large.
This platform technology has the potential to offer better understanding, detection, and treatment of not only endometriosis but also other chronic inflammatory endocrine conditions such as polycystic ovary syndrome and infertility.